NASDAQ:CTMXCytomX Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytomX Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.86 +0.13 (+1.49 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$8.51Now: $8.86▼$9.2450-Day Range$8.40MA: $10.11▼$14.6452-Week Range$3.60Now: $8.86▼$15.44Volume715,116 shsAverage Volume837,910 shsMarket Capitalization$406.85 millionP/E RatioN/ADividend YieldN/ABeta0.78 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, CytomX Therapeutics has a potential upside of 58.0% from its current price of $8.86.Amount of Analyst CoverageCytomX Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesCytomX Therapeutics has received 337 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCytomX Therapeutics has received 258 “underperform” votes. (Add your “underperform” vote.)Community SentimentCytomX Therapeutics has received 56.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote “Outperform” if you believe CTMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $540,000.00 in company stock.Percentage Held by InsidersOnly 6.30% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions78.59% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.48) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX Previous Symbol CUSIPN/A CIK1501989 Webwww.cytomx.com Phone650-515-3185Debt Debt-to-Equity Ratio0.35 Current Ratio3.77 Quick Ratio3.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$57.49 million Price / Sales7.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.52 per share Price / Book5.83Profitability EPS (Most Recent Fiscal Year)($2.26) Net Income$-102,240,000.00 Net Margins-97.83% Return on Equity-99.72% Return on Assets-19.52%Miscellaneous Employees137 Outstanding Shares45,920,000Market Cap$406.85 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:CTMX Rates by TradingView Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions How has CytomX Therapeutics' stock been impacted by COVID-19 (Coronavirus)? CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTMX shares have increased by 50.9% and is now trading at $8.86. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CytomX Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytomX Therapeutics. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for CytomX Therapeutics. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) issued its earnings results on Thursday, May, 7th. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.60. The biotechnology company had revenue of $49.59 million for the quarter, compared to analysts' expectations of $26.93 million. CytomX Therapeutics had a negative net margin of 97.83% and a negative return on equity of 99.72%. View CytomX Therapeutics' earnings history. What price target have analysts set for CTMX? 9 brokers have issued 1-year target prices for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $23.00. On average, they expect CytomX Therapeutics' stock price to reach $14.00 in the next year. This suggests a possible upside of 58.0% from the stock's current price. View analysts' price targets for CytomX Therapeutics. What are Wall Street analysts saying about CytomX Therapeutics stock? Here are some recent quotes from research analysts about CytomX Therapeutics stock: 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/3/2020) 2. Nomura Securities analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019) Has CytomX Therapeutics been receiving favorable news coverage? News stories about CTMX stock have been trending somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CytomX Therapeutics earned a news impact score of -1.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutCytomX Therapeutics. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 1,070,000 shares, a drop of 14.4% from the April 30th total of 1,250,000 shares. Based on an average trading volume of 536,100 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.4% of the shares of the company are sold short. View CytomX Therapeutics' Current Options Chain. Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Dicerna Pharmaceuticals (DRNA), Akcea Therapeutics (AKCA), BELLUS Health (BLUSF), Akebia Therapeutics (AKBA), Y-mAbs Therapeutics (YMAB), Passage Bio (ZNTL), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), CytoDyn (CYDY), Opko Health (OPK), Constellation Pharmaceuticals (CNST), Portola Pharmaceuticals (PTLA) and Intra-Cellular Therapies (ITCI). View all competitors. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), SCYNEXIS (SCYX), Bausch Health Companies (BHC) and Cidara Therapeutics (CDTX). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the following people: Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)Mr. Debanjan Ray, Sr. VP & CFO (Age 41)Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63) What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.65%), Victory Capital Management Inc. (6.04%), Victory Capital Management Inc. (6.04%), State Street Corp (2.15%), First Manhattan Co. (1.73%) and Nuveen Asset Management LLC (1.57%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Lloyd A Rowland and Sean A Mccarthy. View institutional ownership trends for CytomX Therapeutics. Which institutional investors are selling CytomX Therapeutics stock? CTMX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., First Manhattan Co., Squarepoint Ops LLC, Two Sigma Investments LP, Deutsche Bank AG, BlackRock Inc., GSA Capital Partners LLP, and Victory Capital Management Inc.. View insider buying and selling activity for CytomX Therapeutics. Which institutional investors are buying CytomX Therapeutics stock? CTMX stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Granahan Investment Management Inc. MA, Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, Russell Investments Group Ltd., Sumitomo Mitsui Trust Holdings Inc., Thrivent Financial for Lutherans, and Geode Capital Management LLC. View insider buying and selling activity for CytomX Therapeutics. How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $8.86. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $406.85 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe. What is CytomX Therapeutics' official website? The official website for CytomX Therapeutics is www.cytomx.com. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
